Summarized by Masters of Longevity from Frontiers - Health.
A review reframes MASLD as an endocrine-driven disorder and organises its pathogenesis around seven hormonal axes to guide targeted therapies.
Key Takeaways
- Insulin resistance is identified as the central driver linking caloric excess to hepatic de novo lipogenesis.
- Reduced hepatic thyroid hormone sensitivity predicts steatosis and fibrosis and underlies the first approved liver-directed therapy.
- Two drugs, resmetirom and semaglutide, received US FDA accelerated approval for noncirrhotic MASH with moderate-to-advanced fibrosis.
